Brian A. Jonas

9.7k total citations · 3 hit papers
122 papers, 3.5k citations indexed

About

Brian A. Jonas is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Brian A. Jonas has authored 122 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Hematology, 43 papers in Molecular Biology and 37 papers in Genetics. Recurrent topics in Brian A. Jonas's work include Acute Myeloid Leukemia Research (88 papers), Chronic Myeloid Leukemia Treatments (37 papers) and Multiple Myeloma Research and Treatments (24 papers). Brian A. Jonas is often cited by papers focused on Acute Myeloid Leukemia Research (88 papers), Chronic Myeloid Leukemia Treatments (37 papers) and Multiple Myeloma Research and Treatments (24 papers). Brian A. Jonas collaborates with scholars based in United States, Australia and France. Brian A. Jonas's co-authors include Daniel A. Pollyea, Jalaja Potluri, Keith W. Pratz, Courtney D. DiNardo, Brenda Chyla, Andrew H. Wei, Anthony Letai, Marina Konopleva, Martha Arellano and Hagop M. Kantarjian and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Brian A. Jonas

115 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

2018 1.2k citations Courtney D. DiNardo, Keith W. Pratz et al. Blood profile →
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

2018 498 citations Courtney D. DiNardo, Keith W. Pratz et al. profile →
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

2024 47 citations Keith W. Pratz, Courtney D. DiNardo et al. Blood profile →

Peers

Countries citing papers authored by Brian A. Jonas

Since Specialization

Citations

This map shows the geographic impact of Brian A. Jonas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian A. Jonas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian A. Jonas more than expected).

Fields of papers citing papers by Brian A. Jonas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian A. Jonas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian A. Jonas. The network helps show where Brian A. Jonas may publish in the future.

Co-authorship network of co-authors of Brian A. Jonas

This figure shows the co-authorship network connecting the top 25 collaborators of Brian A. Jonas. A scholar is included among the top collaborators of Brian A. Jonas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian A. Jonas. Brian A. Jonas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial 2025 ·Journal of Hematology & Oncology ·Jörge E. Cortes, Gail J. Roboz, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, P. Brent Ferrell, Jay Yang, Eunice S. Wang, William Blum, Alice S. Mims, Hua Tian, (unknown), Stéphane de Botton, Pau Montesinos, Antonio Curti, Justin M. Watts, (unknown)	7
2	A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503) 2025 ·Leukemia Research ·Brian A. Jonas, (unknown), Peter Curtin, Gary J. Schiller, Deepa Jeyakumar, Dimitrios Tzachanis, Rafael Bejar, Lihong Qi, Matthew J. Wieduwilt, Joseph M. Tuscano, Lloyd E. Damon, Aaron C. Logan	0
3	Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia 2024 ·Blood ·Brian A. Jonas, Zarir E. Karanjawala, (unknown), (unknown), Mehrdad Abedi, (unknown), Aaron S. Rosenberg, (unknown), Lihong Qi, Joseph M. Tuscano	1
4	Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia 2024 ·Current Treatment Options in Oncology ·Justin M. Watts, Simon J. Shaw, Brian A. Jonas	7
5	Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia. 2024 ·Journal of Clinical Oncology ·Stéphane de Botton, Brian A. Jonas, P. Brent Ferrell, (unknown), Alice S. Mims	1
6	Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). 2024 ·Journal of Clinical Oncology ·(unknown), Abdul Rafeh Naqash, Reva Schneider, Aditi Shastri, Maximilian Stahl, Justin C. Moser, (unknown), Yazan F. Madanat, Brian A. Jonas, Eytan M. Stein, Shirish M. Gadgeel, James McCloskey, Ashwin Gollerkeri, (unknown), Yogesh K. Chutake, Sagar Agarwal, Patrick Henrick, Kelvin Shi, Naval Daver	6
7	CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial 2024 ·Leukemia & lymphoma ·Caspian Oliai, Sunmin Park, (unknown), Brian A. Jonas, Deepa Jeyakumar, Matthew J. Wieduwilt, Aaron C. Logan, (unknown), Christine Hannigan, Daria Gaut, Gary J. Schiller	0
8	A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia 2023 ·Hematological Oncology ·Brian A. Jonas, Jing‐Zhou Hou, Gail J. Roboz, Caroline Alvares, Deepa Jeyakumar, John Edwards, Harry P. Erba, Richard Kelly, Christoph Röllig, Walter Fiedler, Deanna J. Brackman, (unknown), Brenda Chyla, (unknown), Justin M. Watts	12
9	Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine 2022 ·Clinical Cancer Research ·Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod Pullarkat, Brian A. Jonas, Christian Récher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo	75
10	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients 2021 ·Blood Cancer Journal ·Aaron S. Rosenberg, Ann Brunson, Joseph M. Tuscano, Brian A. Jonas, (unknown), Ted Wun, Theresa H.M. Keegan	13
11	A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia 2021 ·Cancer ·Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, David A. Rizzieri, Thomas Prébet, Christopher S. Chen, Relja Popovic, Dimple Modi, (unknown), Johannes Wolff, Brian A. Jonas	51
12	A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies 2020 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), JULIAN R. DAVIS, Brian A. Jonas, Joseph M. Tuscano, Aaron S. Rosenberg, Mehrdad Abedi	3
13	Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis 2019 ·Blood ·Christina Poh, Paul Frankel, Christopher Ruel, Mehrdad Abedi, (unknown), Caitlin Costello, Jasmine Zain, Lihua E. Budde, Basem M. William, Francine M. Foss, Brian A. Jonas, Aaron S. Rosenberg, Edward M. Newman, Joseph M. Tuscano	25
14	Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia 2019 ·American Journal of Hematology ·Bruno C. Medeiros, Steven M. Chan, Naval Daver, Brian A. Jonas, Daniel A. Pollyea	60
15	Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science 2019 ·Toxics ·Michael Malfatti, Bruce A. Buchholz, Heather A. Enright, Benjamin J. Stewart, Ted Ognibene, (unknown), Gabriela G. Loots, Maike Zimmermann, (unknown), George D. Cimino, Brian A. Jonas, Chong‐Xian Pan, Graham Bench, Paul T. Henderson, Kenneth W. Turteltaub	7
16	Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute‐designated cancer centers in California 2018 ·Cancer ·(unknown), Ted Wun, Lori Muffly, Qian Li, Ann Brunson, Aaron S. Rosenberg, Brian A. Jonas, Theresa H.M. Keegan	44
17	A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401 2018 ·Blood ·Matthew J. Wieduwilt, Brian A. Jonas, Gary J. Schiller, Lin Liu, Carolyn Mulroney, Gabriel N. Mannis, Dimitrios Tzachanis, Januario E. Castro, Edward D. Ball, Peter Curtin, Charalambos Andreadis, Aaron C. Logan, (unknown), Lloyd E. Damon	5
18	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 2018 ·Blood ·Jörge E. Cortes, Justin M. Watts, Thomas Prébet, Gary J. Schiller, Sang‐Min Lee, Jay Yang, Eunice S. Wang, Shira Dinner, P. Brent Ferrell, Will Donnellan, Brian A. Jonas, Andrew H. Wei, Pau Montesinos, (unknown), Patrick Kelly, Ping Li, Jennifer Sweeney, Courtney Watson, Hesham Mohamed, Maria R. Baer	14
19	Retrospective Analysis of Adult Relapsed and Refractory Acute Leukemia Patients Treated with FLAG at a Comprehensive Cancer Center 2017 ·Blood ·(unknown), (unknown), (unknown), Aaron S. Rosenberg, Brian A. Jonas	1
20	Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia 2017 ·SHILAP Revista de lepidopterología ·(unknown), Denis M. Dwyre, Brian A. Jonas	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact